Enliven Therapeutics, Inc. $ELVN Stock: Pictet Asset Management Holding SA Increases Holdings

Pictet Asset Management Holding SA boosted its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 14.1% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,325,740 shares of the company’s stock after buying an additional 163,956 shares during the period. Pictet Asset Management Holding SA’s holdings in Enliven Therapeutics were worth $60,772,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ELVN. BlackRock Inc. acquired a new position in shares of Enliven Therapeutics in the second quarter valued at approximately $221,255,000. First Light Asset Management LLC raised its holdings in shares of Enliven Therapeutics by 574.1% during the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after acquiring an additional 1,158,883 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Enliven Therapeutics by 276.4% during the third quarter. Assenagon Asset Management S.A. now owns 1,153,973 shares of the company’s stock worth $52,898,000 after acquiring an additional 847,399 shares during the period. Siren L.L.C. acquired a new stake in shares of Enliven Therapeutics during the first quarter worth $29,252,000. Finally, Jupiter Topco LLC bought a new stake in Enliven Therapeutics in the 2nd quarter valued at $30,617,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Price Performance

Shares of ELVN stock opened at $51.55 on Tuesday. Enliven Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $62.32. The company’s fifty day simple moving average is $47.13 and its 200-day simple moving average is $43.20.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.09. As a group, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -1.79 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ELVN. Mizuho upped their target price on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 18th. Zacks Research downgraded Enliven Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 13th. Morgan Stanley assumed coverage on Enliven Therapeutics in a research note on Friday, October 2nd. They issued an “overweight” rating and a $70.00 price target on the stock. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Finally, The Goldman Sachs Group upped their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Ten investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $75.44.

Insider Activity

In other news, Director J. Scott Garland sold 13,000 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares in the company, valued at $606,710. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $38.48, for a total value of $231,572.64. Following the completion of the transaction, the chief financial officer owned 38,000 shares of the company’s stock, valued at $1,462,240. The trade was a 13.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 31,054 shares of company stock worth $1,493,823 over the last three months. Insiders own 3.00% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. Its research centers on precision oncology, with drug candidates designed to target specific proteins involved in tumor growth.

The company’s pipeline has included ELVN-001, an investigational BCR-ABL1 inhibitor being studied for chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor developed for cancers driven by HER2.

Enliven is based in Boulder, Colorado.